715 ICT01 plus low dose SC IL-2 produces a robust anti-tumor immune activation in advanced cancer patients (EVICTION-2 Study) - Stephane Champiat; Francois-Xavier Danlos; Volker Kunzmann; Martin Wermke; Aude de Gassart; Daniel Olive; Patrick Brune; Emmanuel Valentin; Johann De Bono; Paul Frohna; Marina Iché; Maelle Mairesse; et al. (Journal for ImmunoTherapy of Cancer, 2023)